Dipeptidyl Peptidase 4
Inhibitors of dipeptidyl peptidase 4 are used to treat type-2 diabetes
Dipeptidyl Peptidase 4 (DPP4)
Treating Type-2 Diabetes
Exploring the Structure
Inhibitors of DPP4
In 2006, the Federal Drug Administration approved the first of these DPP4 inhibitors, sitagliptin (PDB entry 1x70), which was quickly followed by many other anti-diabetic drugs collectively known as “gliptins.” All of these drugs mimic the end of the incretin hormones, blocking the active site of DPP4 so that it cannot inactivate the hormones. To explore six different gliptins and an analog of one of the DPP4 substrates, click on the image for an interactive JSmol.
Topics for Further Discussion
- Structures for several other hormones that are cleaved by DPP4 are available in the PDB, including peptide YY (2dez) and chemokine RANTES (1rtn). Take a look at these and find the dipeptide that is cleaved by DPP4.
- You can use the Protein Feature View of DPP4 to see the portions of the enzyme that are not included in the structure.
October 2016, Sutapa Ghosh, David Goodselldoi:10.2210/rcsb_pdb/mom_2016_10